SynCo Bio Partners, a Dutch GMP contract manufacturer of biological-based vaccines and therapeutics, has added a second Qualified Person (QP), Raoul Fisser, to its quality affairs team.
Dishman Group, of Ahmedabad, India, has appointed Juan Venceslao to the newly created position of director, Dishman Generic API Business.
Professor Frank Bonner is the new chief executive of UK firm Stem Cells for Safer Medicines (SC4SM), the public-private partnership whose aim is to develop stem cell technology for use in early stage medicine testing.
Aesica, a supplier of APIs and formulated products, has strengthened its management team with the addition of John Parker as non-executive chairman and Nick Jones as cfo. Adam Sims, Aesica's current cfo, has taken on the new role of commercial director within the senior team.
Algeta, a Norwegian cancer therapeutics company, has appointed Dr Gillies O'Bryan-Tear as chief medical officer.
Masuo Hosokawa (seated) has stepped down as chief executive of Hosokawa Micron Corporation (HMC) and has become chairman. His successor is Kiyomi Miyata who has been appointed as president and representative director/ceo.
Peter Green has resigned as chairman and director of Patheon in the US. Claudio Bussandri, who joined the board in March 2008, has become the corporation's new chairman.
Cellexus, a supplier of single-use, disposable bioreactors, has appointed Dr Sandy Primrose as a non-executive director, adding key biopharmaceutical expertise.
Genentech has promoted Sandra Horning to senior vice president, global head of clinical development haematology/oncology.
